Accessibility Menu
Third Harmonic Bio logo

Third Harmonic Bio(NASDAQ) THRD

This security has been delisted. This page is retained for historical reference.

Third Harmonic Bio last closing stock price
MetricPriceDate
Last closeUSD 5.382025-07-30
Third Harmonic Bio stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-0.92%USD 5.432025-07-23
1 month-0.92%USD 5.432025-06-30
3 month+4.26%USD 5.162025-05-01
Year to date-47.72%USD 10.292024-12-31
1 year-56.82%USD 12.462024-07-30
Since inception-72.66%USD 19.682022-09-15

THRD News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

THRD Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

16.41%

Return on Capital

20.42%

Return on Assets

15.43%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

-$13.00K

Operating Income

-$66.30M

EBITDA

-$66.25M

Operating Cash Flow

-$41.69M

Capital Expenditure

-$10.00K

Free Cash Flow

-$41.70M

Cash & ST Invst.

$271.61M

Total Debt

$3.00M

Third Harmonic Bio Performance Analysis

Third Harmonic Bio annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20212021-12-31USD 0N/A
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
Third Harmonic Bio sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-06-30N/A
Q32024-09-30N/A
Q42024-12-31N/A
Q12025-03-31-100.0%
Third Harmonic Bio annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20212021-12-31USD -0.77N/A
20222022-12-31USD -0.8916.7%
20232023-12-31USD -0.78-12.9%
20242024-12-31USD -1.0940.1%
Third Harmonic Bio sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-06-30-30.0%
Q32024-09-30226.9%
Q42024-12-31-187.9%
Q12025-03-31-20.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2025YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$13.00K

-8.3%

Gross Margin

N/A

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

31

N/A

Net Income

-$15.83M

-101.6%

EBITDA

-$18.70M

-65.8%

Quarterly Fundamentals

Name
Q1 2025YOY CHG

Total Cash

$271.61M

+3.3%

Total Debt

$3.00M

-20.5%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$2.11M

-29.6%

Short Term Debt

$889.00K

-42.5%

Return on Assets

15.43%

N/A

Return on Invested Capital

20.48%

N/A

Free Cash Flow

-$13.48M

-114.2%

Operating Cash Flow

-$13.48M

-114.2%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
INZYInozyme Pharma, Inc.
$4.00+0.25%
SLRNAcelyrin, Inc.
$2.27+0.00%
SPPISpectrum Pharmaceuticals, Inc.
$1.03-0.49%
CRGXCARGO Therapeutics, Inc. Common Stock
$4.47+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.42-0.04%
NUNu Holdings
$14.09-0.01%
FFord Motor Company
$14.37+0.02%
AALAmerican Airlines Group
$14.48+0.07%

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.